Playback speed
10 seconds
Post ASCO 2021 Expert Panel Discussion on Breast Cancers: Adjuvant Olaparib for High-Risk EBC, Metastatic CDK4/6i, Talazoparib for BRCA1/2-m EBC, PBC vs. Capecitabine for TNBC
181 views
July 7, 2021
Login to view comments.
Click here to Login